Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Operating Expenses (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Other Operating Expenses for 8 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses fell 1.48% year-over-year to $5.9 million, compared with a TTM value of $19.1 million through Sep 2025, down 13.56%, and an annual FY2024 reading of $21.6 million, up 61.49% over the prior year.
  • Other Operating Expenses was $5.9 million for Q3 2025 at Fennec Pharmaceuticals, up from $5.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $12.8 million in Q4 2022 and bottomed at -$10.0 million in Q2 2022.
  • Average Other Operating Expenses over 4 years is $4.1 million, with a median of $5.1 million recorded in 2023.
  • Peak annual rise in Other Operating Expenses hit 124.84% in 2023, while the deepest fall reached 59.95% in 2023.
  • Year by year, Other Operating Expenses stood at $12.8 million in 2022, then crashed by 59.95% to $5.1 million in 2023, then dropped by 10.03% to $4.6 million in 2024, then increased by 27.25% to $5.9 million in 2025.
  • Business Quant data shows Other Operating Expenses for FENC at $5.9 million in Q3 2025, $5.3 million in Q2 2025, and $3.3 million in Q1 2025.